Longitudinal Bladder Cancer Study for Tumour Recurrence
Recruiting now
Conditions studied: Urothelial Bladder Cancer
In brief
Surveillance for recurrence of urothelial carcinoma (UC) requires frequent cystoscopy, which is invasive, expensive and time-consuming. An accurate urinary biomarker has the potential to reduce the number of cystoscopies required during post-treatment surveillance. This is a prospective, single arm, multi-center study using the diagnostic CxBladder test with subjects previously diagnosed with primary or recurrent UC and who are undergoing a schedule of investigative cystoscopies and treatment for the possible recurrence of UC presenting to qualified sites. To evaluate the performance characteristics of the CxBladder test, multiple consecutive urine samples will be collected during the course of surveillance.
Key facts
- Study ID
- NCT05080998
- Run by
- Pacific Edge Limited
- People needed
- 450
- Starts
- 2022-06-08
- Expected to finish
- 2026-08-31
- Last updated by the study team
- 2025-11-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Low-, intermediate-, and high-risk surveillance subjects with a previous confirmed diagnosis or recurrence of urothelial carcinoma within the last 3 calendar years.
- Subjects must agree to 4 successive study visits, including urine sample collection at each visit.
- Physically able to provide a voided urine sample (a sample from catheterization is not eligible).
- Able to give written informed consent
- Able and willing to comply with study requirements
- Aged 18 years or older
You may not qualify if…
- Total cystectomy of the bladder, subjects with neo-bladders or illeal conduits
- Previous muscle invasive bladder tumour (pT2 or greater)
- Known pregnancy
- Deferral Criteria
- Prior genitourinary manipulation (catheterisation, urethral dilation, cystoscopy, etc.) within 14 calendar days of the scheduled urine collection, study enrollment with urine sample collection for Cxbladder Monitor testing should be deferred until a minimum of 14 calendar days has passed since the procedure was performed.
- Active urinary tract infection (UTI) within 14 calendar days of the scheduled urine collection, study enrollment with urine sample collection for Cxbladder Monitor testing should be deferred until the treatment is complete and the UTI is resolved.
- If a subject has had intravesical immunotherapy or chemotherapy within the previous 6 weeks, study enrollment with urine sample collection for Cxbladder Monitor testing should be deferred. Study enrollment must be at least 28 calendar days post-last treatment.
Where it is running
- Miami VA Healthcare System — Miami, Florida, United States (enrolling)
- James A. Haley Veteran's Hospital — Tampa, Florida, United States (enrolling)
- Ralph H. Johnson VA Health Care System — Charleston, South Carolina, United States (enrolling)
- UT Southwestern Medical Center — Dallas, Texas, United States (enrolling)
- White River Junction Veterans Affair Medical Center — White River Junction, Vermont, United States (enrolling)
- University of Washington School of Medicine — Seattle, Washington, United States (enrolling)
- Monash Health - Moorabbin Hospital — Clayton, Victoria, Australia (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.